Butobarbital
Butobarbital, also called butobarbitone or butethal, Soneryl, and Neonal,[1] is a hypnotic drug which is a barbiturate derivative. It was developed by Poulenc Brothers (now part of Rhône Poulenc) in 1921.[2]
![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Soneryl |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Hepatic |
Excretion | Renal |
Identifiers | |
IUPAC name
| |
CAS Number |
|
PubChem CID | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.928 ![]() |
Chemical and physical data | |
Formula | C10H16N2O3 |
Molar mass | 212.249 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(verify) |
References
- International Drug Names
- DE Patent 481129
Hypnotics/sedatives (N05C) | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GABAA |
| ||||||||||||||||||||||||
GABAB |
| ||||||||||||||||||||||||
H1 |
| ||||||||||||||||||||||||
α2-Adrenergic |
| ||||||||||||||||||||||||
5-HT2A |
| ||||||||||||||||||||||||
Melatonin | |||||||||||||||||||||||||
Orexin |
| ||||||||||||||||||||||||
α2δ VDCC |
| ||||||||||||||||||||||||
Others |
|
GABAA receptor positive modulators | |
---|---|
Alcohols |
|
Barbiturates |
|
Benzodiazepines |
|
Carbamates |
|
Flavonoids | |
Imidazoles |
|
Kava constituents |
|
Monoureides |
|
Neuroactive steroids |
|
Nonbenzodiazepines |
|
Phenols | |
Piperidinediones |
|
Pyrazolopyridines |
|
Quinazolinones |
|
Volatiles/gases |
|
Others/unsorted |
|
See also: Receptor/signaling modulators • GABA receptor modulators • GABA metabolism/transport modulators |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.